|International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma|
WD Travis, E Brambilla, M Noguchi, AG Nicholson, KR Geisinger, ...
Journal of thoracic oncology 6 (2), 244-285, 2011
|Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain|
W Pao, VA Miller, KA Politi, GJ Riely, R Somwar, MF Zakowski, MG Kris, ...
PLoS medicine 2 (3), 225, 2005
|Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer|
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinů, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
|Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers|
AY Helena, ME Arcila, N Rekhtman, CS Sima, MF Zakowski, W Pao, ...
Clinical cancer research 19 (8), 2240-2247, 2013
|KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib|
W Pao, TY Wang, GJ Riely, VA Miller, Q Pan, M Ladanyi, MF Zakowski, ...
PLoS medicine 2 (1), e17, 2005
|MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib|
J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ...
Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007
|Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients|
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703, 2017
|Ceritinib in ALK-rearranged non–small-cell lung cancer|
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
N Engl j med 370, 1189-1197, 2014
|Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer|
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
|Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study|
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis|
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
|Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors|
MN Balak, Y Gong, GJ Riely, R Somwar, AR Li, MF Zakowski, A Chiang, ...
Clinical cancer research 12 (21), 6494-6501, 2006
|Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases|
A Yoshizawa, N Motoi, GJ Riely, CS Sima, WL Gerald, MG Kris, BJ Park, ...
Modern pathology 24 (5), 653-664, 2011
|Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer|
D Jackman, W Pao, GJ Riely, JA Engelman, MG Kris, PA Jšnne, T Lynch, ...
Journal of clinical oncology 28 (2), 357, 2010
|Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology|
DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ...
Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017
|OncoKB: a precision oncology knowledge base|
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
|Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib|
GJ Riely, W Pao, DK Pham, AR Li, N Rizvi, ES Venkatraman, ...
Clinical cancer research 12 (3), 839-844, 2006
|Non–small cell lung cancer|
DS Ettinger, W Akerley, G Bepler, MG Blum, A Chang, RT Cheney, ...
Journal of the national comprehensive cancer network 8 (7), 740-801, 2010
|Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study|
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020